What Analysts Expect from Sanofi’s 3Q17 Earnings
A look at Sanofi
Sanofi (SNY), one of the largest pharmaceutical companies, is set to release its 3Q17 earnings on November 2, 2017. Wall Street analysts estimate the company will report earnings per share (or EPS) of 1.71 euros on revenues of 9.4 billion euros during 3Q17.
Interested in FVD? Don't miss the next report.
Receive e-mail alerts for new research on FVD
The above chart shows revenues and EPS over the last few quarters and estimates for 3Q17. For 2Q17, the company reported operational growth of 5.5% in revenues to 8.7 billion euros as compared to 8.1 billion euros during 2Q16. Also, the company surpassed Wall Street analysts’ EPS estimates with reported EPS of 1.35 euros in 2Q17 as compared to estimates of 1.32 euros.
3Q17 revenue estimates
Sanofi is expected to report a 2.2% decline in revenues to 9.4 billion euros during 3Q17 as compared to 9.7 billion euros during 3Q16. The revenues will likely fall due to lower sales of diabetes and cardiovascular products as well as lower sales of established products. However, Sanofi Genzyme will likely substantially offset the decline in revenues for Sanofi during 3Q17.
Analysts estimate Sanofi’s gross profit margin will fall 1.2% to 70.6% during 3Q17 as compared to the gross profit margin of 71.8% during 3Q16. Also, the EBITDA margin is expected to fall 0.5% to 35.8% during 3Q17 as compared to 36.3% during 3Q16. The EBITDA margin is expected to decrease due to the increase in research and development expenses during 3Q17. The net adjusted income is expected to increase to 2.1 billion euros during 3Q17 as compared to 2.3 billion euros in 3Q16.